Arthritis and Rheumatology… Spring 2025 Press Review – Arthritis & Rheumatology 12 May 2025 December 2024 to March 2025 Authors: Clementina López-Medina and Rym Abida Clinical factors associated with pneumocystis pneumonia despite its primary prophylaxis: When to stop prophylaxis? Kim, JY et al. (doi:10.1002/art.43167/abs) aimed…
Arthritis Research and Therapy… Spring 2025 Press Review – Arthritis Research & Therapy 12 May 2025 December 2024 to March 2025 Authors: Antony Psarras and Rositsa Dacheva Differences in the response to TNF inhibitors at distinct joint locations in patients with psoriatic arthritis: results from nine European…
Press Review… Spring 2025 Press Review – Lancet Rheumatology 12 May 2025 December 2024 to March 2025 Author: Antony Psarras and Rositsa Dacheva Cenerimod, a sphingosine-1-phosphate receptor modulator, versus placebo in patients with moderate-to-severe systemic lupus erythematosus (CARE): an international, double-blind, randomised,…
Miscellaneous… Spring 2025 Press Review – Miscellaneous 12 May 2025 December 2024 to March 2025 Authors: Valentina Pucino and Jacob Koopman A Phase-3 Study on the Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis Furie R, et al. (doi:10.1056/NEJMoa2410965) conducted…
Rheumatology (Oxford) Spring 2025 Press Review – Rheumatology (Oxford) 12 May 2025 December 2024 to March 2025 Authors: Slaverio La Bella & Stephanie Ling Immune checkpoint inhibitors-induced large vessel vasculitis: clinical characteristics and management from a European multicentre study Immune checkpoint inhibitors (ICIs)…
Press Review… Spring 2025 Press Review – RMD Open 12 May 2025 December 2024 to March 2025 Author: Victoria Konzett & Mustafa Ekici Switching to biological DMARDs versus cycling among JAK inhibitors in patients with rheumatoid arthritis and with inadequate response to JAK…
Press Review… Spring 2025 Press Review – Seminars in Arthritis and Rheumatism 12 May 2025 December 2024 to March 2025 Authors: Slaverio La Bella & Stephanie Ling Real-world effectiveness of nintedanib in RA-ILD Atienza-Mateo B, et al. (doi:10.1016/j.semarthrit.2025.152710) assessed the real-world effectiveness and safety of nintedanib…
Annals of the Rheumatic Diseases… Winter 2025 Press Review – Annals of Rheumatic Diseases 2 Feb 20254 Feb 2025 August 2024 to November 2024 Author: Krystel Aouad & Victoria Sadovici-Bobeica EULAR recommendations for the treatment of systemic sclerosis: 2023 update The updated 2023 EULAR recommendations (10.1136/ard-2024-226430) for the treatment…
Press Review… Winter 2025 Press Review – Lancet Rheumatology 2 Feb 2025 August 2024 to November 2024 Authors: Halbert Hernández Negrin and Magda Osipyan Nirmatrelvir–Ritonavir Reduces Mortality and Sequelae in Immunocompromised COVID-19 Patients Lin et al. (10.1016/S2665-9913(24)00224-8) investigated the impact of nirmatrelvir–ritonavir…
Rheumatology (Oxford) Winter 2025 Press Review – Rheumatology (Oxford) 2 Feb 2025 August 2024 to November 2024 Authors: Milena Bond & Ufuk Ilgen Cancer Risk Factors in Idiopathic Inflammatory Myopathies Tang et al. (10.1093/rheumatology/keae504) validated the International Myositis Assessment and Clinical Studies Group…